Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Aspirin, NSAIDs, and Glioma Risk: Original Data from the Glioma International Case-Control Study and a Meta-analysis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Childhood overweight, tallness and growth increase risks of ovarian cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Determinants for participation in human papillomavirus self-sampling among non-attenders to cervical cancer screening in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • E Susan Amirian
  • Quinn T Ostrom
  • Georgina N Armstrong
  • Rose K Lai
  • Xiangjun Gu
  • Daniel I Jacobs
  • Ali Jalali
  • Elizabeth B Claus
  • Jill S Barnholtz-Sloan
  • Dora Il'yasova
  • Joellen M Schildkraut
  • Francis Ali-Osman
  • Siegal Sadetzki
  • Robert B Jenkins
  • Daniel H Lachance
  • Sara H Olson
  • Jonine L Bernstein
  • Ryan T Merrell
  • Margaret R Wrensch
  • Christoffer Johansen
  • Richard S Houlston
  • Michael E Scheurer
  • Sanjay Shete
  • Christopher I Amos
  • Beatrice Melin
  • Melissa L Bondy
Vis graf over relationer

BACKGROUND: There have been few studies of sufficient size to address the relationship between glioma risk and the use of aspirin or NSAIDs, and results have been conflicting. The purpose of this study was to examine the associations between glioma and aspirin/NSAID use, and to aggregate these findings with prior published studies using meta-analysis.

METHODS: The Glioma International Case-Control Study (GICC) consists of 4,533 glioma cases and 4,171 controls recruited from 2010 to 2013. Interviews were conducted using a standardized questionnaire to obtain information on aspirin/NSAID use. We examined history of regular use for ≥6 months and duration-response. Restricted maximum likelihood meta-regression models were used to aggregate site-specific estimates, and to combine GICC estimates with previously published studies.

RESULTS: A history of daily aspirin use for ≥6 months was associated with a 38% lower glioma risk, compared with not having a history of daily use [adjusted meta-OR = 0.62; 95% confidence interval (CI), 0.54-0.70]. There was a significant duration-response trend (P = 1.67 × 10-17), with lower ORs for increasing duration of aspirin use. Duration-response trends were not observed for NSAID use. In the meta-analysis aggregating GICC data with five previous studies, there was a marginally significant association between use of aspirin and glioma (mOR = 0.84; 95% CI, 0.70-1.02), but no association for NSAID use.

CONCLUSIONS: Our study suggests that aspirin may be associated with a reduced risk of glioma.

IMPACT: These results imply that aspirin use may be associated with decreased glioma risk. Further research examining the association between aspirin use and glioma risk is warranted.

OriginalsprogEngelsk
TidsskriftCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Vol/bind28
Udgave nummer3
Sider (fra-til)555-562
Antal sider8
ISSN1055-9965
DOI
StatusUdgivet - mar. 2019

Bibliografisk note

©2018 American Association for Cancer Research.

ID: 57384357